Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2385-2390

  Alder, J D ^a   Ewing, P J ^a   Nilius, A M ^a   Mitten, M ^a   Tovcimak, A ^a   Oleksijew, A ^a   Jarvis, K ^a   Paige, L ^a   Tanaka, S K T ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN;

ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0031710249     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2385     Document Type: Article

References (26)

1. Alder, J. D. 1997. Determining the therapeutic potential of experimental antibacterial agents: the use of animal models. Curr. Pharm. Design 3:143-158.
2. Baldwin, D. R., R. Wise, J. M. Andrews, J. P. Ashby, and D. Honeybourn. 1990. Azithromycin concentrations at the sites of pulmonary infection. Eur. Respir. J. 3:886-890.
3. Barry, A. L., P. J. Fuchs, and S. D. Brown. 1995. Relative potencies of azithromycin, clarithromycin, and five orally administrated antibiotics. J. Antimicrob. Chemother. 35:552-555.
4. Baurnfeind, A., R. Jungwirth, and E. Eberlein. 1995. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. Infection 23:316-321.
5. Bonnett, M., and P. Van der Auwera. 1992. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob. Agents Chemother. 36:1302-1309.
6. Chavanet, P., N. Peyrard, A. Pechinot, M. Buisson, M. Duong, C. Neuwirth, A. Kazmierczak, and H. Portier. 1996. In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2062-2066.
7. Conte, J. E., Jr., J. Golden, S. Duncan, E. McKenna, E. Lin, and E. Zurlinden. 1996. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. 40:1617-1622.
8. Conte, J. E., Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden. 1995. Intrapulmonary pharmacokinetics of clarithromycin and of azithromycin. Antimicrob. Agents Chemother. 39:334-338.
9. Fass, R. J. 1993. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analysis to compare in vitro activities and describe cross-resistance. Antimicrob. Agents Chemother. 37:2080-2086.
10. Fernandez, P. B., N. Ramer, R. A. Rode, and L. A. Freiberg. 1988. Bioassay for A-5626K (TE-031) and identification of its major metabolite. 14-hydroxy-6-O-methyl erythromycin. Eur. J. Clin. Microbiol. Infect. Dis. 7:73-76.
11. Ferrero, J. L., B. A. Bopp, and K. C. Marsh. 1990. Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. 18:441-446.
12. Forsgren, J., A. Samuelson, J. Jonasson, B. Rynnel-Dagoo, and A. Lindberg. 1994. Haemophilus influenzae resides and multiplies intracellularly in human adenoid tissue as demonstrated by in situ hybridization and bacterial viability assay. Infect. Immun. 62:673-679.
13. Foulds, G., R. M. Shephard, and R. B. Johnson. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl. A):73-82.
14. Frimodt-Moller, N., M. W. Bentzon, and V. F. Thomsen. 1986. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J. Infect. Dis. 154:511-517.
15. Hardy, D. J., R. N. Swanson, R. A. Rode, K. Marsh, N. L. Shipkowitz, and J. Clement. 1990. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilia influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob. Agents Chemother. 34:1407-1413.
16. Hollander, M., and D. A. Wolfe. 1973. Nonparametric statistical methods p. 129-132. John Wiley & Sons, New York, N.Y.
17. Jones, R. N., G. V. Doern, E. H. Gerlach, J. Hindler, and M. E. Erwin. 1994. Validation of the NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards. Diagn. Microbiol. Infect. Dis. 18:243-249.
18. Kees, F., M. Wellenhofer, and H. Grobecker. 1995. Serum and cellular pharmacokinetics of clarithromycin 500 mg o.d. and 250 mg b.i.d. in volunteers. Infection 23:108-172.
19. Loos, U., and F. Kees. 1991. Bronchopulmonary disposition of clarithromycin, abstr. 441. In Proceedings of the 17th International Congress of Chemotherapy. University Hospital of Bonn, Bonn, Germany, and University of Regensburg, Regensburg, Germany.
20. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
21. Nilius, A. M., J. M. Beyer, R. K. Flamm, and S. K. Tanaka. 1997. Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH. J. Clin. Microbiol. 35:1311-1315.
22. Peters, D. H., H. A. Friedel, and D. McTavish. 1992. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44:750-799.
23. Ritche, D. J., A. W. Hopefl, T. W. Mulligan, J. E. Byrne, and M. S. Maddux. 1993. In vitro activity of clarithromycin, celprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens. Clin. Ther. 15:107-113.
24. Scaglione, F., G. Demartini, S. Dugnani, and F. Fraschini. 1993. A new model examining intracellular and extracellular activity of amoxicillin, azithromycin, and clarithromycin in infected cells. Exp. Chemother. 39:416-423.
25. Williams, J. D., J. P. Maskel, H. Shain, G. Chrysos, A. M. Sefton, H. Y. Fraser, and J. M. Hardie. 1992. Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J. Antimicrob. Chemother. 30:27-37.
26. Zuckerman, J. M., and K. M. Kaye. 1995. The newer macrolides azithromycin and clarithromycin. Infect. Dis. Clin. N. Am. 9:731-745.